



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Intrastromal Corneal Ring Segments is addressed separately in medical policy 00164.

When Services Are Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider the Boston (Dohlman-Doane) Keratoprosthesis (Boston KPro) for the surgical treatment of severe corneal opacification in situations where cadaveric corneal transplants have failed or have a very low likelihood of success under the following conditions to be **eligible for coverage.****

- The cornea is severely opaque and vascularized; AND
- Best-corrected vision is 20/400 or less in the affected eye and 20/40 or less in the contralateral eye AND
- No end-stage glaucoma or retinal detachment is present AND
- The patient has one of the following indications:
 - History of one or more corneal transplant graft failures; or
 - Stevens-Johnson syndrome; or
 - Ocular cicatricial pemphigoid; or
 - Autoimmune conditions with rare ocular involvement; or
 - Ocular chemical burns; or
 - An ocular condition unlikely to respond favorably to primary corneal transplant surgery (eg, limbal stem cell compromise or postherpetic anesthesia)

Note: Individuals should be able and expected to comply with postoperative care.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers a permanent keratoprosthesis for all other conditions to be **investigational**.*

Based on review of available data, the Company considers all other types of permanent keratoprosthesis to be **investigational**.*

Policy Guidelines

Implantation of a keratoprosthesis is considered a high-risk procedure associated with numerous complications and probable need for additional surgery. Therefore, the likelihood of regaining vision and the patient's visual acuity in the contralateral eye should be taken into account when considering the appropriateness of this procedure. Treatment should be restricted to centers experienced in treating this condition and staffed by surgeons adequately trained in techniques addressing implantation of this device.

Background/Overview

Cornea

The cornea, a clear, dome-shaped membrane that covers the front of the eye, is a key refractive element of sight. Layers of the cornea consist of the epithelium (outermost layer); Bowman layer; the stroma, which comprises approximately 90% of the cornea; Descemet membrane; and the endothelium.

Treatment

The established surgical treatment for corneal disease is penetrating keratoplasty, which involves making a large central opening through the cornea and then filling the opening with a full-thickness donor cornea. In certain conditions, such as Stevens-Johnson syndrome, ocular cicatricial pemphigoid, chemical injury, or prior failed corneal transplant, survival of transplanted cornea is poor. The keratoprosthesis was developed to restore vision in individuals for whom a corneal transplant is not an option.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

Keratoprosthetic devices consist of a central optic held in a cylindrical frame. The keratoprosthesis replaces the section of the cornea that has been removed, and, along with being held in place by the surrounding tissue, may be covered by a membrane to further anchor the prosthesis. A variety of biologic materials are being investigated to improve the integration of prosthetic corneal implants into the stroma and other corneal layers.

The Dohlman-Doane keratoprosthesis, most commonly referred to as the Boston Keratoprosthesis (KPro), is manufactured under the auspices of the Harvard Medical School affiliated Massachusetts Eye and Ear Infirmary. The Boston type 1 KPro uses a donor cornea between a central stem and a back plate. The Boston type 2 prosthesis is a modification of the type 1 prosthesis and is designed with an anterior extension to allow implantation through surgically closed eyelids. The AlphaCor, previously known as the Chirila keratoprosthesis (Chirila KPro), consists of a polymethylmethacrylate device with a central optic region fused to a surrounding sponge skirt; the device is inserted in a 2-stage surgical procedure.

Autologous keratoprostheses use a central polymethylmethacrylate optic supported by a skirt of either tibia bone or the root of a tooth with its surrounding alveolar bone. The most common is the osteo-odonto-keratoprosthesis, which uses osteodental lamina derived from an extracted tooth root and attached alveolar bone that has been removed from the patient's jaw. Insertion of the osteo-odonto-keratoprosthesis device requires a complex staged procedure, in which the cornea is first covered with buccal mucosa. The prosthesis itself consists of a polymethylmethacrylate optical cylinder, which replaces the cornea, and is held in place by biologic support made from a canine tooth extracted from the recipient. A hole is drilled through the dental root and alveolar bone, and the polymethylmethacrylate prosthesis is placed within. This entire unit is placed into a subcutaneous ocular pocket and is then retrieved 6 to 12 months later for final insertion.

Hydroxyapatite, with a similar mineral composition to both bone and teeth (phosphate and calcium), may also be used as a bone substitute and as a bioactive prosthesis with the orbit. Collagen coating and scaffolds have also been investigated to improve growth and biocompatibility with the corneal epithelial cells, which form the protective layer of the eye. Many of these materials and devices are currently being tested in vitro or animal models.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

In 1992, the Boston KPro (Dohlman-Doane keratoprosthesis; Massachusetts Eye and Ear Infirmary) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process for use in individuals with severe corneal opacity. The device is used when standard corneal transplant has failed or would be unlikely to succeed. There are 2 types of Boston KPro. Type 1 is used in eyes when eyelids, blink mechanism, and tear film are intact. Type 2 is used with severe dry eye and in eyes with mucosal keratinization and obliteration of normal conjunctival fornices.

In August 2002, the AlphaCor^{®‡} (Chirila Keratoprosthesis) was cleared for marketing by the FDA through the 510(k) process. The FDA determined that this device was substantially equivalent to the Dolman-Doane keratoprosthesis. The AlphaCor^{®‡} device is indicated as a keratoprosthesis in adults with corneal opacity when standard penetrating keratoplasty with donor tissue is not suitable, when individuals have declined standard penetrating keratoplasty, or when adjunctive procedures to prevent graft rejection are contraindicated.

FDA product code: HQM

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

A keratoprosthesis, consisting of a central optic held in a cylindrical frame, is an artificial cornea intended to restore vision to individuals with severe bilateral corneal disease for whom a corneal transplant is not an option. The keratoprosthesis replaces the cornea that has been removed and is held in place by the surrounding tissue. Various biologic materials are being investigated to improve integration of the prosthetic into the eye.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

Summary of Evidence

For individuals who have corneal blindness and have failed or are not candidates for corneal transplantation who receive a Boston Keratoprosthesis (Boston KPro), the evidence includes case series and systematic reviews. Relevant outcomes are change in disease status, morbid events, quality of life, and treatment-related morbidity. Numerous case series have been published. Together, studies have assessed thousands of eyes. A 2015 systematic review of Boston KPro efficacy included 22 series with a total of 2,176 eyes. Systematic reviews and case series with longer follow-up (ie, at least 2 years) have shown improvement in visual outcomes in a substantial percentage of individuals with Boston KPro. This procedure is high-risk and associated with numerous complications (eg, the growth of retro prosthetic membranes) and a probable need for additional surgery, thus careful patient selection is important. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have corneal blindness and have failed or are not candidates for corneal transplantation who receive a keratoprosthesis using the AlphaCor device, the evidence includes case series. Relevant outcomes are change in disease status, morbid events, quality of life, and treatment-related morbidity. Only a few published case series have evaluated the AlphaCor device. There are insufficient data on improvement in vision outcomes using the AlphaCor device. Moreover, the device has been associated with complications, including thinning or melting of the anterior corneal surface and corneal necrosis. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have corneal blindness and have failed, or are not candidates for corneal transplantation who receive an osteo-odonto-keratoprosthesis, the evidence includes case series and a systematic review. Relevant outcomes are change in disease status, morbid events, quality of life, and treatment-related morbidity. A 2012 systematic review of case series, all conducted outside of the United States, found high anatomic survival rates at 5 and 20 years, but vision outcomes were not well-described. Long-term follow-up of a case series of 229 eyes reported cumulative probability of anatomic survival exceeding 80% and probability of functional success of approximately 60% with 40-year follow-up. Osteo-odonto-keratoprosthesis is a complex surgical procedure and has been associated with a number of complications, including extrusion of the keratoprosthesis, retinal detachment, and vitreoretinal complications. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 1 specialty society and 4 academic medical centers while this policy was under review in 2009. Reviewers generally supported a limited role for the Boston Keratoprosthesis in select individuals. Some reviewers recommended use without first attempting a transplant under specific conditions that have a poor prognosis for corneal transplant; however, others found this controversial. Some reviewers recommended use only in individuals with limited visual acuity in the contralateral eye. Overall, input indicated that the Boston Keratoprosthesis should be reserved for cases in which no other alternative (ie, corneal transplantation) is available for treatment of corneal opacification.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Ophthalmology

The 2018 Preferred Practice Parameter on ocular edema and opacification by the American Academy of Ophthalmology did not provide specific recommendations on the keratoprosthesis, but discussed the technology and its current use:

“Significant improvements in the design and postoperative management of the Boston type 1 keratoprosthesis has resulted in a steady rise in the number of these procedures performed both in the United States and abroad. Reduced incidence of postoperative stromal necrosis and bacterial endophthalmitis due to the chronic use of protective soft contact lenses and topical antibiotics has resulted in improved retention and visual outcomes and has had a positive impact on surgeons’

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

perceptions of when to recommend keratoprosthesis. Once considered a procedure of last resort in individuals with severe bilateral visual impairment, it is now being used for a variety of unilateral and bilateral indications, such as ocular trauma, herpetic keratitis, aniridia, and Stevens-Johnson syndrome. More recently, as corneal surgeons have gained a greater appreciation of the failure rate of repeat corneal transplantation, a role for a keratoprosthesis in cases of multiple graft failure has become clearer. Despite earlier suggestions, keratoprosthetics are not considered ideal for pediatric cases, particularly as primary treatment....

“Individuals with severe dry eye and autoimmune ocular surface diseases...remain a difficult management group despite the other successes of the Boston type 1 keratoprosthesis. Primary placement of the Boston keratoprosthesis in this group of individuals results in a higher rate of epithelial defects, scleral and corneal necrosis, extrusion, and endophthalmitis. Some surgeons advocate ocular surface reconstruction with combined keratolimbal allografts or living related allografts prior to placement of the keratoprosthesis. This can potentially lead to improved outcomes in this group. The Boston type 2 keratoprosthesis designed to be used through the eyelid and the osteo-odonto-keratoprosthesis have been implanted with some success in this group of individuals.”

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no Medicare national coverage policy.

Ongoing and Unpublished Clinical Trials

Some currently ongoing trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT05694247	A Single Arm, Open Label, Multicenter Clinical Investigation to Evaluate the Clinical Safety and	40	Mar 2025

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

	performance of the CorNeat Keratoprosthesis, for Treatment of Corneal Blindness		
--	---	--	--

NCT: national clinical trial.

References

1. Matthaei M, Sandhaeger H, Hermel M, et al. Changing Indications in Penetrating Keratoplasty: A Systematic Review of 34 Years of Global Reporting. *Transplantation*. Jun 2017; 101(6): 1387-1399. PMID 27336399
2. Kohanim S, Palioura S, Saeed HN, et al. Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. *Ocul Surf*. Apr 2016; 14(2): 168-88. PMID 26882981
3. Nonpassopon M, Niparugs M, Cortina MS. Boston Type 1 Keratoprosthesis: Updated Perspectives. *Clin Ophthalmol*. 2020; 14: 1189-1200. PMID 32425503
4. Holland G, Pandit A, Sánchez-Abella L, et al. Artificial Cornea: Past, Current, and Future Directions. *Front Med (Lausanne)*. 2021; 8: 770780. PMID 34869489
5. Ortiz-Morales G, Loya-Garcia D, Colorado-Zavala MF, et al. The evolution of the modified osteo-odonto-keratoprosthesis, its reliability, and long-term visual rehabilitation prognosis: An analytical review. *Ocul Surf*. Apr 2022; 24: 129-144. PMID 35314421
6. Lee WB, Shtein RM, Kaufman SC, et al. Boston Keratoprosthesis: Outcomes and Complications: A Report by the American Academy of Ophthalmology. *Ophthalmology*. Jul 2015; 122(7): 1504-11. PMID 25934510
7. Ahmad S, Mathews PM, Lindsley K, et al. Boston Type 1 Keratoprosthesis versus Repeat Donor Keratoplasty for Corneal Graft Failure: A Systematic Review and Meta-analysis. *Ophthalmology*. Jan 2016; 123(1): 165-77. PMID 26545318
8. Ciolino JB, Belin MW, Todani A, et al. Retention of the Boston keratoprosthesis type 1: multicenter study results. *Ophthalmology*. Jun 2013; 120(6): 1195-200. PMID 23499061
9. Rudnisky CJ, Belin MW, Guo R, et al. Visual Acuity Outcomes of the Boston Keratoprosthesis Type 1: Multicenter Study Results. *Am J Ophthalmol*. Feb 2016; 162: 89-98.e1. PMID 26550696
10. Srikumaran D, Munoz B, Aldave AJ, et al. Long-term outcomes of boston type 1 keratoprosthesis implantation: a retrospective multicenter cohort. *Ophthalmology*. Nov 2014; 121(11): 2159-64. PMID 25017414

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

11. Rudnisky CJ, Belin MW, Todani A, et al. Risk factors for the development of retroprosthetic membranes with Boston keratoprosthesis type 1: multicenter study results. *Ophthalmology*. May 2012; 119(5): 951-5. PMID 22361316
12. Dunlap K, Chak G, Aquavella JV, et al. Short-term visual outcomes of Boston type 1 keratoprosthesis implantation. *Ophthalmology*. Apr 2010; 117(4): 687-92. PMID 20096462
13. Odorcic S, Haas W, Gilmore MS, et al. Fungal Infections After Boston Type 1 Keratoprosthesis Implantation: Literature Review and In Vitro Antifungal Activity of Hypochlorous Acid. *Cornea*. Dec 2015; 34(12): 1599-605. PMID 26488624
14. Chan CC, LoVerde L, Qiang J, et al. Incidence, Risk Factors, and Surgical Management of Boston Type 1 Keratoprosthesis Corneal Melts, Leaks, and Extrusions. *Cornea*. Aug 2016; 35(8): 1049-56. PMID 27391092
15. Goldman DR, Hubschman JP, Aldave AJ, et al. Postoperative posterior segment complications in eyes treated with the Boston type I keratoprosthesis. *Retina*. Mar 2013; 33(3): 532-41. PMID 23073339
16. Hicks CR, Crawford GJ, Lou X, et al. Corneal replacement using a synthetic hydrogel cornea, AlphaCor: device, preliminary outcomes and complications. *Eye (Lond)*. Apr 2003; 17(3): 385-92. PMID 12724702
17. Crawford GJ, Hicks CR, Lou X, et al. The Chirila Keratoprosthesis: phase I human clinical trial. *Ophthalmology*. May 2002; 109(5): 883-9. PMID 11986092
18. Hoffart L, Carles G, Matonti F. Lamellar corneal lenticule graft to treat keratolysis after AlphaCor keratoprosthesis implantation. *Eur J Ophthalmol*. 2015; 25(1): 1-7. PMID 25198171
19. Tan A, Tan DT, Tan XW, et al. Osteo-odonto keratoprosthesis: systematic review of surgical outcomes and complication rates. *Ocul Surf*. Jan 2012; 10(1): 15-25. PMID 22330056
20. Falcinelli G, Falsini B, Taloni M, et al. Modified osteo-odonto-keratoprosthesis for treatment of corneal blindness: long-term anatomical and functional outcomes in 181 cases. *Arch Ophthalmol*. Oct 2005; 123(10): 1319-29. PMID 16219722
21. Colliardo P, Taloni A, Taloni M, et al. Follow-up Extension Up to 43 Years of Modified Osteo-Odonto-Keratoprosthesis. *Ophthalmology*. Sep 2023; 130(9): 995-997. PMID 37182745
22. Michael R, Charoenrook V, de la Paz MF, et al. Long-term functional and anatomical results of osteo- and osteodonto-keratoprosthesis. *Graefes Arch Clin Exp Ophthalmol*. Aug 2008; 246(8): 1133-7. PMID 18491123
23. De La Paz MF, De Toledo JÁ, Charoenrook V, et al. Impact of clinical factors on the long-term functional and anatomic outcomes of osteo-odonto-keratoprosthesis and tibial bone keratoprosthesis. *Am J Ophthalmol*. May 2011; 151(5): 829-839.e1. PMID 21310387

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

24. Hughes EH, Mokete B, Ainsworth G, et al. Vitreoretinal complications of osteodontokeratoprosthesis surgery. *Retina*. Oct 2008; 28(8): 1138-45. PMID 18779721
25. Liu C, Okera S, Tandon R, et al. Visual rehabilitation in end-stage inflammatory ocular surface disease with the osteo-odonto-keratoprosthesis: results from the UK. *Br J Ophthalmol*. Sep 2008; 92(9): 1211-7. PMID 18511541
26. Farid M, Rhee MK, Akpek EK, et al. Corneal Edema and Opacification Preferred Practice Pattern®. *Ophthalmology*. Jan 2019; 126(1): P216-P285. PMID 30366795

Policy History

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

- | | |
|------------|--|
| 05/07/2015 | Medical Policy Committee review |
| 05/20/2015 | Medical Policy Implementation Committee approval. New policy. |
| 05/05/2016 | Medical Policy Committee review |
| 05/18/2016 | Medical Policy Implementation Committee approval. A bullet stating “an ocular condition unlikely to respond favorably to primary corneal transplant surgery” was added to the medically necessary policy statement. In medically necessary policy statement, “multiple graft failures changed” to “history of 1 or more” graft failures. |
| 01/01/2017 | Coding update: Removing ICD-9 Diagnosis Codes |
| 05/04/2017 | Medical Policy Committee review |
| 05/17/2017 | Medical Policy Implementation Committee approval. No change to coverage. |
| 05/03/2018 | Medical Policy Committee review |
| 05/16/2018 | Medical Policy Implementation Committee approval. No change to coverage. |
| 05/02/2019 | Medical Policy Committee review |
| 05/15/2019 | Medical Policy Implementation Committee approval. Coverage eligibility unchanged. |
| 05/07/2020 | Medical Policy Committee review |
| 05/13/2020 | Medical Policy Implementation Committee approval. Coverage eligibility unchanged. |
| 05/06/2021 | Medical Policy Committee review |
| 05/12/2021 | Medical Policy Implementation Committee approval. Coverage eligibility unchanged. |
| 05/05/2022 | Medical Policy Committee review |

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

05/11/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

05/04/2023 Medical Policy Committee review

05/10/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

05/02/2024 Medical Policy Committee review

05/08/2024 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 05/2025

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2023 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	65770
HCPCS	C1818, L8609
ICD-10 Diagnosis	All related diagnoses

***Investigational** – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

****Medically Necessary** (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Keratoprosthesis

Policy # 00450

Original Effective Date: 05/20/2015

Current Effective Date: 06/10/2024

- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.